SE9802073D0 - New use - Google Patents

New use

Info

Publication number
SE9802073D0
SE9802073D0 SE9802073A SE9802073A SE9802073D0 SE 9802073 D0 SE9802073 D0 SE 9802073D0 SE 9802073 A SE9802073 A SE 9802073A SE 9802073 A SE9802073 A SE 9802073A SE 9802073 D0 SE9802073 D0 SE 9802073D0
Authority
SE
Sweden
Prior art keywords
asthma
episodes
solvate
prevention
treatment
Prior art date
Application number
SE9802073A
Other languages
English (en)
Swedish (sv)
Inventor
Tommy Ekstroem
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20411658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9802073(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9802073A priority Critical patent/SE9802073D0/xx
Publication of SE9802073D0 publication Critical patent/SE9802073D0/xx
Priority to ARP990102532A priority patent/AR018410A1/es
Priority to TW088109070A priority patent/TWI252756B/zh
Priority to MYPI99002351A priority patent/MY129281A/en
Priority to SA99200234A priority patent/SA99200234B1/ar
Priority to JP2000553082A priority patent/JP2002517450A/ja
Priority to EP03002381A priority patent/EP1316311A1/de
Priority to EEP200000740A priority patent/EE05661B1/xx
Priority to HU0103108A priority patent/HUP0103108A3/hu
Priority to AU46710/99A priority patent/AU771715B2/en
Priority to SI9931006T priority patent/SI1085877T1/sl
Priority to NZ536279A priority patent/NZ536279A/en
Priority to US09/367,950 priority patent/US20010049396A1/en
Priority to CNB998072303A priority patent/CN100389771C/zh
Priority to EP10178172A priority patent/EP2266574A1/de
Priority to ES99930103T priority patent/ES2302384T3/es
Priority to TR2000/03666T priority patent/TR200003666T2/xx
Priority to RU2000131218/14A priority patent/RU2222332C2/ru
Priority to PL99344665A priority patent/PL344665A1/xx
Priority to AT99930103T priority patent/ATE389409T1/de
Priority to PCT/SE1999/001031 priority patent/WO1999064014A1/en
Priority to IDW20002566A priority patent/ID27937A/id
Priority to PT99930103T priority patent/PT1085877E/pt
Priority to DE69938390T priority patent/DE69938390T2/de
Priority to KR1020007013993A priority patent/KR20010052721A/ko
Priority to EP99930103A priority patent/EP1085877B1/de
Priority to DK99930103T priority patent/DK1085877T3/da
Priority to CA002334411A priority patent/CA2334411C/en
Priority to UA2000126983A priority patent/UA87956C2/uk
Priority to SK1888-2000A priority patent/SK286252B6/sk
Priority to IL13992199A priority patent/IL139921A0/xx
Priority to BR9911073-3A priority patent/BR9911073A/pt
Priority to CZ20004593A priority patent/CZ300874B6/cs
Priority to IL139921A priority patent/IL139921A/en
Priority to ZA200006943A priority patent/ZA200006943B/en
Priority to IS5752A priority patent/IS5752A/is
Priority to NO20006253A priority patent/NO20006253L/no
Priority to HK01105814A priority patent/HK1035145A1/xx
Priority to US10/665,240 priority patent/US9295644B2/en
Priority to CY20081100507T priority patent/CY1110376T1/el
Priority to NO20130269A priority patent/NO20130269L/no
Priority to NO20140823A priority patent/NO20140823L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE9802073A 1998-06-11 1998-06-11 New use SE9802073D0 (sv)

Priority Applications (42)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use
ARP990102532A AR018410A1 (es) 1998-06-11 1999-05-28 Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
TW088109070A TWI252756B (en) 1998-06-11 1999-06-01 Use of a composition comprising formoterol and budesonide for the manufacture of a medicament for the treatment of asthma when needed
MYPI99002351A MY129281A (en) 1998-06-11 1999-06-09 Use of a composition comprising formoterol and budesonide for the prevention or treatment of a acute condition of asthma
SA99200234A SA99200234B1 (ar) 1998-06-11 1999-06-09 استخدام تركيبة تشتمل على فورموتيرول formoterol وبيوديسونيد budesonide للوقاية من او علاج حالات الربو الحادة
BR9911073-3A BR9911073A (pt) 1998-06-11 1999-06-10 Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
CZ20004593A CZ300874B6 (cs) 1998-06-11 1999-06-10 Lécivo pro prevenci nebo lécení akutních astmatických stavu
AT99930103T ATE389409T1 (de) 1998-06-11 1999-06-10 Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
KR1020007013993A KR20010052721A (ko) 1998-06-11 1999-06-10 급성 천식 질환의 예방 또는 치료를 위한 포르모테롤 및부데소니드를 포함하는 조성물의 용도
EEP200000740A EE05661B1 (et) 1998-06-11 1999-06-10 Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks
HU0103108A HUP0103108A3 (en) 1998-06-11 1999-06-10 Use of composition comprising formoterol and budesonide for the prevention of an acute condition of asthma
AU46710/99A AU771715B2 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
SI9931006T SI1085877T1 (sl) 1998-06-11 1999-06-10 Uporaba sestavka, ki obsega formoterol in budezonid, za preprečevanje ali zdravljenje akutnega stanja
NZ536279A NZ536279A (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for symptomatic relief, when needed, in the prevention or treatment of an acute condition of asthma
US09/367,950 US20010049396A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
CNB998072303A CN100389771C (zh) 1998-06-11 1999-06-10 含有福莫特罗和布地奈德的组合物在制备预防和治疗急性气喘疾病的药物的应用
EP10178172A EP2266574A1 (de) 1998-06-11 1999-06-10 Therapeutische bedarfsabhängige Verwendung von Formoterol und Budesonide
ES99930103T ES2302384T3 (es) 1998-06-11 1999-06-10 Uso de una composicion que comprende formoterol y budesonida para la prevencion o tratamiento de un estado agudo de asma.
TR2000/03666T TR200003666T2 (tr) 1998-06-11 1999-06-10 Akut bir astım vakasının önlenmesi , tedavisi için formoterol
RU2000131218/14A RU2222332C2 (ru) 1998-06-11 1999-06-10 Применение композиции, содержащей формотерол и будесонид, для лечения острого состояния астмы
PL99344665A PL344665A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
JP2000553082A JP2002517450A (ja) 1998-06-11 1999-06-10 喘息の急性状態の予防または処置のための、ホルモテロールおよびブデソニドを含んでなる組成物の使用
PCT/SE1999/001031 WO1999064014A1 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
IDW20002566A ID27937A (id) 1998-06-11 1999-06-10 Penggunaan komposisi yang mengandung formoterol dan budesonida untuk pencegahan atau pengobatan kondisi asma yang akut
PT99930103T PT1085877E (pt) 1998-06-11 1999-06-10 Utilização de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de um estado agudo de asma
DE69938390T DE69938390T2 (de) 1998-06-11 1999-06-10 Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
EP03002381A EP1316311A1 (de) 1998-06-11 1999-06-10 Therapeutische bedarfsabhängige Verwendung von Formoterol und Budesonide
EP99930103A EP1085877B1 (de) 1998-06-11 1999-06-10 Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
DK99930103T DK1085877T3 (da) 1998-06-11 1999-06-10 Anvendelse af en sammensætning, der omfatter formoterol og budesonid, til forebyggelsen eller behandlingen af en akut tilstand af astma
CA002334411A CA2334411C (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
UA2000126983A UA87956C2 (uk) 1998-06-11 1999-06-10 Застосування композиції з формотеролом та будезонідом як додаткової терапії для попередження чи лікування гострих астматичних станів
SK1888-2000A SK286252B6 (sk) 1998-06-11 1999-06-10 Použitie kompozície obsahujúcej formoterol a budesonid
IL13992199A IL139921A0 (en) 1998-06-11 1999-06-10 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
ZA200006943A ZA200006943B (en) 1998-06-11 2000-11-27 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma.
IL139921A IL139921A (en) 1998-06-11 2000-11-27 Use of a preparation containing formoterol and budesonide for the manufacture of a drug for the prevention or treatment of an extreme condition of asthma
IS5752A IS5752A (is) 1998-06-11 2000-12-05 Notkun á blöndu sem inniheldur formóteról og búdesóníð til að fyrirbyggja eða meðhöndla bráða-asma
NO20006253A NO20006253L (no) 1998-06-11 2000-12-08 Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand
HK01105814A HK1035145A1 (en) 1998-06-11 2001-08-17 Use of a composition comprising formoterol and budesonide for the prevention or treatment of an acute condition of asthma
US10/665,240 US9295644B2 (en) 1998-06-11 2003-09-19 Methods and compositions for treating asthma
CY20081100507T CY1110376T1 (el) 1998-06-11 2008-05-13 Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος
NO20130269A NO20130269L (no) 1998-06-11 2013-02-18 Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand.
NO20140823A NO20140823L (no) 1998-06-11 2014-06-27 Anvendelse av et preparat omfattende formoterol og budesonid for forebyggelse eller behandling av en akutt astmatilstand

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use

Publications (1)

Publication Number Publication Date
SE9802073D0 true SE9802073D0 (sv) 1998-06-11

Family

ID=20411658

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802073A SE9802073D0 (sv) 1998-06-11 1998-06-11 New use

Country Status (35)

Country Link
US (2) US20010049396A1 (de)
EP (3) EP1085877B1 (de)
JP (1) JP2002517450A (de)
KR (1) KR20010052721A (de)
CN (1) CN100389771C (de)
AR (1) AR018410A1 (de)
AT (1) ATE389409T1 (de)
AU (1) AU771715B2 (de)
BR (1) BR9911073A (de)
CA (1) CA2334411C (de)
CY (1) CY1110376T1 (de)
CZ (1) CZ300874B6 (de)
DE (1) DE69938390T2 (de)
DK (1) DK1085877T3 (de)
EE (1) EE05661B1 (de)
ES (1) ES2302384T3 (de)
HK (1) HK1035145A1 (de)
HU (1) HUP0103108A3 (de)
ID (1) ID27937A (de)
IL (2) IL139921A0 (de)
IS (1) IS5752A (de)
MY (1) MY129281A (de)
NO (3) NO20006253L (de)
NZ (1) NZ536279A (de)
PL (1) PL344665A1 (de)
PT (1) PT1085877E (de)
RU (1) RU2222332C2 (de)
SA (1) SA99200234B1 (de)
SE (1) SE9802073D0 (de)
SK (1) SK286252B6 (de)
TR (1) TR200003666T2 (de)
TW (1) TWI252756B (de)
UA (1) UA87956C2 (de)
WO (1) WO1999064014A1 (de)
ZA (1) ZA200006943B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CZ303833B6 (cs) 2000-05-22 2013-05-22 Chiesi Farmaceutici S.P.A. Aerosolový prostredek
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2464656C (en) 2001-11-01 2013-07-16 Nektar Therapeutics Spray drying methods and compositions thereof
FI20020126A0 (fi) * 2002-01-23 2002-01-23 Orion Corp Koostumuksia pulmonaaliseen antoon
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (ja) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド 乾燥粉末吸入組成物の製造方法
GB0219512D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070098644A1 (en) * 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
JP2010519195A (ja) 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
EP1982709A1 (de) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Verwendung einer Zusammensetzung mit Formoterol und Beclomethason-Dipropionat zur Vorbeugung oder Behandlung von akutem Asthma
AU2010253776B2 (en) 2009-05-29 2015-01-22 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
PT2538922T (pt) * 2010-02-25 2016-07-11 Andi-Ventis Ltd Formulação de composições para o tratamento de doenças inflamatórias
BR112013001119A2 (pt) * 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
EP2464346A1 (de) 2010-08-30 2012-06-20 Pulmatrix, Inc. Behandlung zystischer fibrose mit calciumlactat, leukin und natriumchlorid in einem einatembaren trockenpulver
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
RU2504382C1 (ru) * 2012-06-13 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2017108917A1 (en) * 2015-12-22 2017-06-29 Astrazeneca Ab Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease
IT202000006442A1 (it) 2020-03-27 2021-09-27 Genetic S P A Budesonide 21-phosphate salts and pharmaceutical compositions containing the same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203401A (en) 1979-01-29 1980-05-20 General Motors Corporation Evaporative emissions canister
CA2024872C (en) 1989-09-08 2002-07-09 James Barry Douglas Palmer Medicaments
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5119791A (en) 1991-06-07 1992-06-09 General Motors Corporation Vapor storage canister with liquid trap
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
EP1101493A3 (de) 1991-12-18 2004-01-14 AstraZeneca AB Neue Verwendung von Budesonide und Formoterol
US5408977A (en) 1993-08-23 1995-04-25 Walbro Corporation Fuel tank with carbon canister and shut-off valve
DK0721331T3 (da) 1993-10-01 2002-02-11 Astrazeneca Ab Fremgangsmåde
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5511957A (en) 1994-09-27 1996-04-30 Walbro Corporation High capacity fuel pump and filter combination
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
TR199800924T2 (xx) 1995-11-24 1998-08-21 Smithkline Beecham S.P.A. Quinoline t�revleri.
US5651349A (en) 1995-12-11 1997-07-29 Chrysler Corporation Purge system flow monitor and method
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2295076A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag New combination of antiasthma medicaments
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US5957114A (en) 1998-07-17 1999-09-28 Ford Motor Company Evaporative emission canister for an automotive vehicle
US5924410A (en) 1998-07-20 1999-07-20 Ford Motor Company Evaporative emission canister for an automotive vehicle
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6227862B1 (en) * 1999-02-12 2001-05-08 Advanced Drivers Education Products And Training, Inc. Driver training system
EP1031725B1 (de) 1999-02-26 2004-12-29 Walbro Corporation Fahrzeugbrennstoffsystem
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination
US6237574B1 (en) 1999-04-20 2001-05-29 Ford Motor Company Evaporative emission canister for an automotive vehicle
US6136075A (en) 1999-05-03 2000-10-24 Westvaco Corporation Automotive evaporative emissions canister adsorptive restraint system
JP3646217B2 (ja) 1999-07-08 2005-05-11 愛三工業株式会社 キャニスタモジュール
US6374811B1 (en) 2000-10-04 2002-04-23 Ford Global Technologies, Inc. System and method for minimizing fuel evaporative emissions from an internal combustion engine

Also Published As

Publication number Publication date
CN1305380A (zh) 2001-07-25
CZ20004593A3 (cs) 2001-04-11
HUP0103108A2 (hu) 2002-05-29
PT1085877E (pt) 2008-05-13
AR018410A1 (es) 2001-11-14
NZ536279A (en) 2007-01-26
DK1085877T3 (da) 2008-06-09
DE69938390D1 (de) 2008-04-30
ES2302384T3 (es) 2008-07-01
TR200003666T2 (tr) 2001-06-21
NO20006253L (no) 2001-02-12
SA99200234B1 (ar) 2007-03-10
UA87956C2 (uk) 2009-09-10
DE69938390T2 (de) 2009-03-05
CN100389771C (zh) 2008-05-28
US9295644B2 (en) 2016-03-29
AU771715B2 (en) 2004-04-01
IL139921A0 (en) 2002-02-10
KR20010052721A (ko) 2001-06-25
SK286252B6 (sk) 2008-06-06
JP2002517450A (ja) 2002-06-18
CZ300874B6 (cs) 2009-09-02
AU4671099A (en) 1999-12-30
HUP0103108A3 (en) 2002-11-28
US20010049396A1 (en) 2001-12-06
CA2334411A1 (en) 1999-12-16
IL139921A (en) 2006-10-05
TWI252756B (en) 2006-04-11
BR9911073A (pt) 2001-02-20
ZA200006943B (en) 2002-02-27
NO20130269L (no) 2001-02-12
ID27937A (id) 2001-05-03
RU2222332C2 (ru) 2004-01-27
EP1085877A1 (de) 2001-03-28
CY1110376T1 (el) 2015-04-29
ATE389409T1 (de) 2008-04-15
PL344665A1 (en) 2001-11-19
NO20006253D0 (no) 2000-12-08
WO1999064014A1 (en) 1999-12-16
EP1316311A1 (de) 2003-06-04
NO20140823L (no) 2001-02-12
US20040063676A1 (en) 2004-04-01
SK18882000A3 (sk) 2001-07-10
CA2334411C (en) 2008-07-15
EP2266574A1 (de) 2010-12-29
HK1035145A1 (en) 2001-11-16
IS5752A (is) 2000-12-05
MY129281A (en) 2007-03-30
EP1085877B1 (de) 2008-03-19
EE05661B1 (et) 2013-06-17
EE200000740A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
SE9802073D0 (sv) New use
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
CA2125665A1 (en) Medicaments
CA2474479A1 (en) Composition for inhalation
CA2302700A1 (en) New use for budesonide and formoterol
CA2125666A1 (en) Medicaments
EA200100338A1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
ATE319427T1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
CA2123909A1 (en) New combination of formoterol and budesonide
MX9605650A (es) Formulaciones de propionato de fluticasona.
PH27594A (en) Medicaments for the treatment of asthma and other respiratory disorders
SE9603669D0 (sv) New combination
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
SE9704644D0 (sv) New use
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
AP1849A (en) Dosage regimen and pharmaceutical composition for emergency contraception
SE9901573D0 (sv) New compounds
CA2136404A1 (fr) Composition solide mucoadhesive, therapeutique ou hygienique, pour administration par application sur la muqueuse buccale ou nasale
DE69935526D1 (de) Supramolekulare komplexe enthaltende arzneimittel
KR950016760A (ko) 치질 치료제
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
BE2016C017I2 (de)
WO2000066550A8 (en) New compounds